Stanford Team Gets $13M to Crack ALS With AI

A Stanford research team just got a powerful new weapon in the fight against ALS: $13 million and artificial intelligence tools that didn't even exist a year ago.

The California Institute for Regenerative Medicine awarded the grant to geneticist Michael Snyder and his colleagues to investigate why people develop amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. In ALS, motor neurons gradually die, leading to muscle weakness, paralysis, and eventually death.

The mystery has always been complicated. While some ALS cases stem from a single genetic mutation, most result from a complex mix of multiple genes and environmental factors working together.

That's where the new AI comes in. Snyder's team is using advanced artificial intelligence to scan DNA and find genes and regulatory regions that differ between people with and without ALS. They're looking beyond motor neurons to examine other brain cell types, since different genes may contribute to the disease in different cells.

The approach is already working. The researchers have identified one gene previously unknown to be associated with ALS, and they're hunting for more. "You don't want to put all your eggs in one basket; you want to find more genes like this," Snyder said.

The team plans to test their findings in ALS cell models to see if altering these genes can change the signs of disease. If successful, each discovery could become a new target for treatment development.

The Ripple Effect

This research won't just benefit Stanford's labs. The team is committed to sharing all their findings publicly so scientists worldwide can build on the work. Every gene they discover gives researchers developing ALS treatments more targets to pursue and more information to work with.

For the estimated 31,000 Americans living with ALS right now, that means more shots on goal. More potential treatments in development. More reasons for hope.

Snyder said he's excited about bringing together experts from various fields with AI tools that open entirely new possibilities. It's the kind of collaboration that just wasn't possible until recently.

The race to understand and treat ALS just got a serious boost, and the finish line feels a little closer.